NHS Supply Chain to supply 28 cutting-edge radiotherapy machines in 2025/26

NHS Supply Chain is supplying 28 new linear accelerator (LINAC) radiotherapy systems in 2025/26 to NHS cancer centres across the country.

NHS Supply Chain to supply 28 cutting-edge radiotherapy machines in 2025/26

The rollout of the new technology is backed by centralised government funding provided by NHS England for hospitals in need of replacement systems.

Through its framework agreement, NHS Supply Chain procured 28 new systems for the NHS from three suppliers, Varian Medical Systems UK, Elekta, and Accuray UK, delivering savings of £21.8m for the NHS.

The technology reduces delays to treatment and, in some cases, could reduce the number of hospital visits a patient needs to make by half, helping to cut waiting lists faster. 

NHS national clinical director for cancer, Professor Peter Johnson, said: 'These machines will deliver more precise treatment for patients, which helps them to recover sooner, as well as enabling the NHS to treat people more efficiently as we continue in our efforts to catch and treat more cancers faster.'

Antonia Marks, director – diagnostics, equipment and services at NHS Supply Chain, added: 'These advanced technologies will play a vital role in reducing waiting times and backlogs, while ensuring patients receive treatment using the latest innovations.'

The systems have been purchased via NHS Supply Chain's Imaging Radiotherapy Endoscopy Ancillary Devices and Related Goods and Services framework.

Preparing for Martyn's Law

Preparing for Martyn's Law

14 May 2026

Chris Wimshurst, director of sales UK, AddSecure UK, explains how robust communications can prepare hospitals for Martyn’s Law

BREAKING NEWS: Healthcare reacts to Wes Streeting resignation

By Lee Peart 14 May 2026

Healthcare leaders have given a mixed verdict on Wes Streeting’s tenure as health and social care secretary following his resignation.

BREAKING NEWS: NHS hits interim 18-week waiting target

By Lee Peart 14 May 2026

The NHS has hit its interim target of 65% of patients receiving treatment within 18 weeks by March 2026.


Popular articles by Liz Wells